BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced that the Antimicrobials Drug Advisory Committee of the U.S. Food and Drug Administration voted in favor of the approval of intravenous (IV) and…Original Article
FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline
